Eksempler på bruk av Subcutaneous formulation på Engelsk og deres oversettelse til Norsk
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The bioavailability for the subcutaneous formulation was 79.
Biotilgjengelighet for subkutan formulering var 79.MabThera subcutaneous formulation was given at a fixed dose of 1400 mg.
MabThera subkutan formulering ble gitt som en fast dose på 1400 mg.Description of selected adverse reactions with the subcutaneous formulation.
Beskrivelse av utvalgte bivirkninger med subkutan formulering.Herceptin subcutaneous formulation was locally and systemically well tolerated.
Herceptin subkutan formulering var lokalt og systemisk godt tolerert.Some adverse events/ reactions were reported with a higher frequency for the subcutaneous formulation.
Noen bivirkninger ble rapportert med en høyere frekvens for den subkutane formuleringen.Absorption parameters of subcutaneous formulation, decreased with increasing BMI.
Absorpsjonsparametre ved subkutan formulering ble redusert med økende BMI.Switching treatment between Herceptin intravenous and Herceptin subcutaneous formulation and vice versa.
Bytte av behandling mellom Herceptin intravenøs og Herceptin subkutan formulering og omvendt.Herceptin subcutaneous formulation in administration system is ready to use.
Oppløsning med Herceptin subkutan formulering i et administrasjonssystem er klart til bruk.Hypertension: 4.7% versus 9.8% for the intravenous formulation versus subcutaneous formulation respectively.
Hypertensjon: 4,7 % versus 9,8 % for henholdsvis The recommended dose for Herceptin subcutaneous formulation is 600 mg irrespective of the patient's body weight.
Anbefalt dose for Herceptin subkutan formulering er 600 mg uavhengig av pasientens kroppsvekt.Local cutaneous reactions including injection site reactions were very common in patients receiving MabThera subcutaneous formulation.
Lokale hudreaksjoner, inkludert reaksjoner på injeksjonsstedet var svært vanlige hos pasienter som fikk MabThera subkutan formulering.Clinical experience of MabThera subcutaneous formulation in Non-Hodgkin's lymphoma.
Klinisk erfaring med MabThera subkutan formulering til non-Hodgkin-lymfom.Herceptin subcutaneous formulation is a ready to use solution which should not be mixed or diluted with other products.
Oppløsning med Herceptin subkutan formulering er klar for bruk og skal ikke blandes eller fortynnes Clinical experience of MabThera subcutaneous formulation in Non-Hodgkin's lymphoma.
Klinisk erfaring med MabThera subkutan formulering ved Non-Hodgkins lymfom.MabThera subcutaneous formulation is not intended for intravenous administration and should be given via subcutaneous injection only.
MabThera subkutan formulering er ikke ment til intravenøs administrering og må kun gis via Administration related reactions have been observed in up to 50% of patients treated with MabThera subcutaneous formulation in clinical trials.
Administrasjonsrelaterte reaksjoner har vært observert hos opptil 50 % av pasienter behandlet med MabThera subkutan formulering i kliniske studier.Clinical experience of MabThera subcutaneous formulation in chronic lymphocytic leukaemia.
Klinisk erfaring med MabThera subkutan formulering i kronisk lymfatisk leukemi.Premedication consisting of an analgesic/antipyretic andan antihistamine should always be administered before each dose of MabThera subcutaneous formulation.
Premedisinering bestående av et analgetikum/antipyretikum oget antihistamin bør alltid administreres før hver dose av MabThera subkutan formulering.Therefore, the switch to MabThera subcutaneous formulation can only occur at the second or subsequent cycles of treatment.
Bytte til subkutan formulering kan derfor kun forekomme ved 2. eller senere behandlingssykluser.The clinical relevance of the development of anti-rituximab oranti-rHuPH20 antibodies after treatment with MabThera subcutaneous formulation is not known.
Den kliniske relevansen av utviklingen av anti-rituksimab elleranti-rHuPH20 antistoffer etter behandling med MabThera subkutan formulering er ikke kjent.MabThera 1600 mg subcutaneous formulation should be administered as subcutaneous injection only, over approximately 7 minutes.
MabThera 1600 mg subkutan formulering skal kun gis som Post-operative wound infections(severe and/or serious): 1.7% versus 3.0% for the intravenous formulation versus subcutaneous formulation.
Post-operative sårinfeksjoner(vanskelige og/eller alvorlige): 1,7 % The interval between consecutive Herceptin subcutaneous formulation administrations should not be less than three weeks.
Intervallet mellom etterfølgende administreringer med Herceptin subkutan formulering bør ikke være mindre enn tre uker.InSABRINA, severe administration-related reactions(grade≥3) were reported in two patients(2%)following administration of MabThera subcutaneous formulation.
I SABRINA studien ble alvorlig administrasjonsrelaterte reaksjoner(grad≥ 3) rapportert hos to pasienter(2 %)etter administrering av MabThera subkutan formulering.Single doses of up to 960 mg of Herceptin subcutaneous formulation have been administered with no reported untoward effects.
Enkeltdoser på opp til 960 mg av Herceptin subkutan formulering har blitt administrert uten noen rapporterte uønskede bivirkninger.In the clinical study comparing these two formulations, infections andcardiac events leading to hospitalisation were more frequent with the subcutaneous formulation.
I The recommended dose for Herceptin subcutaneous formulation in administration system is 600 mg irrespective of the patient's body weight.
Anbefalt dose for Herceptin subkutan formulering i et administrasjonssystem er 600 mg uavhengig av pasientens kroppsvekt.Administration-related reactions: 37.2% versus 47.8% for the intravenous formulation versus subcutaneous formulation, respectively during the treatment phase;
Administrasjonsrelaterte reaksjoner under behandlingsfasen: 37,2 % versus 47,8 % i henholdsvis In the pivotal trial(BO22227)Herceptin subcutaneous formulation was administered in the neoadjuvant/adjuvant setting in patients with early breast cancer.
I den pivotale studien(BO22227)ble Herceptin subkutan formuleringen administrert i en neoadjuvant/adjuvant setting hos pasienter med brystkreft i tidlig stadium.If the patient misses a dose of Herceptin subcutaneous formulation, it is recommended to administer the next 600 mg dose(i.e. the missed dose) as soon as possible.
Hvis pasienten avstår fra en Herceptin-dose med subkutan formulering, anbefales det å administrere neste 600 mg dose(dvs. den tapte dosen) så raskt som mulig.
